EMA Authorised: Attrogy (diflunisal) — Purpose Pharma International AB

View source ↗

Summary

The EMA has authorised Attrogy (diflunisal) by Purpose Pharma International AB for familial amyloid polyneuropathy, marking EU marketing authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloid Polyneuropathy

Drugs mentioned

• Attrogy (diflunisal)

Snippet

Status: Authorised. Therapeutic area: Amyloid Neuropathies, Familial. MAH: Purpose Pharma International AB. Decision date: 11/12/2025